Completed
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
Learn MoreCompleted
Immunogenicity and efficacy study of Fluviral® influenza vaccine strategies in HIV infected Adults: Trial results
Learn MoreOngoing
A study of an HPV VLP vaccine in a cohort of HIV positive girls and women
Learn MoreCompleted
A pilot study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART: Trial results
Learn MoreTerminated
Open label, dose escalating phase I/II study of TG4040 (MVA-HCV) in patients chronically infected with hepatitis C virus (Genotype I) who relapsed from previous pegylated interferon/ribavirin treatment
Learn MoreCompleted
A Phase I/II safety and immunogencity study of a combination of whole-killed HIV-1 antigen and Amplivax, administered with or without IFA, in HIV-1 infected Participants: Trial results
Learn MoreCompleted
A pilot study to determine the impact of therapeutic HIV vaccination followed by a scheduled interruption of antiretroviral therapy on HIV-specific immune function and virologic rebound in patients with prolonged viral suppression: Trial results
Learn MoreCompleted
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients: Trial results
Learn MoreCompleted
A pilot study assessing the efficacy of pneumococcal vaccine in HIV patients: delayed versus immediate immunization: Trial results
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
